Translational Development Acquisition Corp.
corporate_fare Company Profile
Translational Development Acquisition Corp. (NASDAQ:TDAC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 23 items for TDAC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for TDAC spans 8-K, 10-Q, 425, DEF 14A.
Recent high-impact activity:
- TDAC Amends ProLogium Merger: $3.9B Equity Value, 4.16 Consolidation Factor
- TDAC Q3 10-Q: Going Concern Warning, $85,852 Cash, $50M ProLogium Subscription Disclosed
- ProLogium Unveils GEN4 Battery with Third-State Electrolyte at Paris Motor Show
- TDAC's Q2 10-Q Flags Ineffective Disclosure Controls and Going Concern Risk
- TDAC Locks In $50M PIPE from Naetas Holding, Complete with Warrants and Registration Rights
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 2,736 shares in TDAC as of the October 30, 2026 settlement, a 37.8% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 0.0% of TDAC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.